Advertisement

Der Ophthalmologe

, Volume 115, Issue 2, pp 157–160 | Cite as

Progrediente Ulzerationen der Periorbita

  • A. Frings
  • V. Frings
  • G. Geerling
  • M. Goebeler
  • M. Schargus
Bild und Fall

Progressive ulceration of the periorbital region

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

A. Frings, V. Frings, G. Geerling, M. Goebeler und M. Schargus geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.

Literatur

  1. 1.
    Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G (2009) Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 23:1008–1017CrossRefPubMedGoogle Scholar
  2. 2.
    Binus AM, Qureshi AA, Li VW, Winterfield LS (2011) Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 165:1244–1250CrossRefPubMedGoogle Scholar
  3. 3.
    Powell FC, Schroeter AL, Su WP, Perry HO (1985) Pyoderma gangrenosum: a review of 86 patients. Q J Med 55:173–186PubMedGoogle Scholar
  4. 4.
    Gupta AS, Ortega-Loayza AG (2017) Ocular pyoderma gangrenosum: a systematic review. J Am Acad Dermatol 76(3):512–518. doi: 10.1016/j.jaad.2016.08.049 CrossRefPubMedGoogle Scholar
  5. 5.
    von den Driesch P (1997) Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 137:1000–1005CrossRefPubMedGoogle Scholar
  6. 6.
    Callen JP (1998) Pyoderma gangrenosum. Lancet 351:581–585CrossRefPubMedGoogle Scholar
  7. 7.
    Camargo CM, Brotas AM, Ramos-e-Silva M, Carneiro S (2013) Isomorphic phenomenon of Koebner: facts and controversies. Clin Dermatol 31:741–749CrossRefPubMedGoogle Scholar
  8. 8.
    Tolkachjov SN, Fahy AS, Wetter DA, Brough KR, Bridges AG, Davis MD, El-Azhary RA, McEvoy MT, Camilleri MJ (2015) Postoperative pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014. J Am Acad Dermatol 73:615–622CrossRefPubMedGoogle Scholar
  9. 9.
    Su WPD, Davis MDP, Weenig RH, Powell FC, Perry HO (2004) Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 43:790–800CrossRefPubMedGoogle Scholar
  10. 10.
    Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP (2000) Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 79:37–46CrossRefGoogle Scholar
  11. 11.
    Al Ghazal P, Herberger K, Schaller J, Strölin A, Hoff NP, Goerge T, Roth H, Rabe E, Karrer S, Renner R, Maschke J, Horn T, Hepp J, Eming S, Wollina U, Zutt M, Sick I, Splieth B, Dill D, Klode J, Dissemond J (2013) Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis 8:136CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Al Ghazal P, Korber A, Klode J, Dissemond J (2012) Investigation of new co-factors in 49 patients with pyoderma gangrenosum. J Dtsch Dermatol Ges 10:251–257PubMedGoogle Scholar
  13. 13.
    Ye MJ, Ye JM (2014) Pyoderma gangrenosum: a review of clinical features and outcomes of 23 cases requiring inpatient management. Dermatol Res Pract 2014:461467CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Shore RN (1976) Pyoderma gangrenosum, defective neutrophil chemotaxis, and leukemia. Arch Dermatol 112:1792–1793CrossRefPubMedGoogle Scholar
  15. 15.
    Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR (2010) Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 62:646–654CrossRefPubMedGoogle Scholar
  16. 16.
    Wollina U (2002) Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 3:149–158CrossRefPubMedGoogle Scholar
  17. 17.
    Kaddoura IL, Amm C (2001) A rationale for adjuvant surgical intervention in pyoderma gangrenosum. Ann Plast Surg 46:23–28CrossRefPubMedGoogle Scholar
  18. 18.
    Cabalag MS, Wasiak J, Lim SW, Raiola FB (2015) Inpatient management of pyoderma gangrenosum: treatments, outcomes, and clinical implications. Ann Plast Surg 74:354–360CrossRefPubMedGoogle Scholar
  19. 19.
    Alam M, Grossman ME, Schneiderman PI, Blume RS, Benvenisty AI (2000) Surgical management of pyoderma gangrenosum: case report and review. Dermatol Surg 26:1063–1066CrossRefPubMedGoogle Scholar
  20. 20.
    Le Cleach L, Moguelet P, Perrin P, Chosidow O (2011) Is topical monotherapy effective for localized pyoderma gangrenosum? Arch Dermatol 147:101–103CrossRefPubMedGoogle Scholar
  21. 21.
    Nybaek H, Olsen AG, Karlsmark T, Jemec GB (2004) Topical therapy for peristomal pyoderma gangrenosum. J Cutan Med Surg 8:220–223CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  • A. Frings
    • 1
  • V. Frings
    • 2
  • G. Geerling
    • 1
  • M. Goebeler
    • 2
  • M. Schargus
    • 1
    • 3
    • 4
  1. 1.Univ.-Klinik für AugenheilkundeHeinrich-Heine-UniversitätDüsseldorfDeutschland
  2. 2.Klinik und Poliklinik für Dermatologie, Venerologie und AllergologieUniversitätsklinikum WürzburgWürzburgDeutschland
  3. 3.MVZ Augenheilkunde SchweinfurtSchweinfurtDeutschland
  4. 4.Augenklinik GerolzhofenGerolzhofenDeutschland

Personalised recommendations